|
Phospholipid and Sphingolipid Signaling in Drosophila
|
ZIA BC 010331
|
$147,835
|
Acharya, Jairaj
|
CCR (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$755,842
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Natural History and Specimen Banking for Patients with CNS Tumors
|
ZIA BC 011768
|
$548,393
|
Armstrong, Terri
|
CCR (NCI)
|
|
Studies of amplification in rhabdomyosarcoma
|
ZIA BC 011378
|
$218,891
|
Barr, Frederic
|
CCR (NCI)
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,094,457
|
Barr, Frederic
|
CCR (NCI)
|
|
(PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors
|
5R21CA208723-02
|
$177,852
|
BETTEGOWDA, CHETAN
|
JOHNS HOPKINS UNIVERSITY
|
|
Development of Natural Product Leads as Anticancer Therapeutics
|
ZIA BC 011470
|
$312,747
|
Beutler, John
|
CCR (NCI)
|
|
Oncogenic Met Signaling in Urologic Malignancies
|
ZIA BC 011124
|
$356,352
|
Bottaro, Donald
|
CCR (NCI)
|
|
BKV and JCV vaccine development
|
ZIA BC 011460
|
$362,249
|
Buck, Christopher
|
CCR (NCI)
|
|
Stable Water Isotope Labeling for Imaging of Rapidly Proliferating Cells
|
ZIA BC 011777
|
$24,641
|
Buxbaum, Nataliya
|
CCR (NCI)
|
|
Molecular Profiling of Patients Undergoing Radiotherapy
|
ZIA SC 010372
|
$427,230
|
Camphausen, Kevin
|
CCR (NCI)
|
|
The Synergy Between Radiotherapy and Molecularly Targeted Agents
|
ZIA SC 010373
|
$640,845
|
Camphausen, Kevin
|
CCR (NCI)
|
|
Radiation Oncology Branch - Radiation Clinic
|
ZID BC 010990
|
$4,983,045
|
Camphausen, Kevin
|
CCR (NCI)
|
|
Study of Anti-Survival signals in NF1
|
5R01CA153354-06
|
$225,443
|
CHEN, CHANGYAN
|
NORTHEASTERN UNIVERSITY
|
|
Targeting the Kinome in Neurofibromatosis type 1
|
5R01CA142928-08
|
$434,625
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Elucidating the Regulation and Function of the NF1 tumor suppressor
|
5R01CA111754-12
|
$316,635
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Developmental and HyperActive Ras Tumor SPORE
|
5U54CA196519-03
|
$2,271,783
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Basic and Preclinical Animal Models in support of Cancer and HIV-AIDS Research
|
ZIG BC 010856
|
$14,497,944
|
Custer, Mary
|
CCR (NCI)
|
|
Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways
|
ZIA BC 010006
|
$427,953
|
Daar, Ira
|
CCR (NCI)
|
|
Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion
|
ZIA BC 010958
|
$427,953
|
Daar, Ira
|
CCR (NCI)
|
|
Role of Neurogenic Inflammation in Pancreatic Cancer
|
5R01CA177857-05
|
$418,087
|
DAVIS, BRIAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Mayo Comprehensive Cancer Center Grant
|
3P30CA015083-43S1
|
$60,000
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Mayo Comprehensive Cancer Center Grant
|
3P30CA015083-43S2
|
$75,000
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Mayo Comprehensive Cancer Center Grant
|
3P30CA015083-43S3
|
$749,911
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
Mayo Comprehensive Cancer Center Grant
|
5P30CA015083-43
|
$5,815,389
|
DIASIO, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
OHSU Knight Cancer Institute
|
2P30CA069533-19
|
$2,310,000
|
DRUKER, BRIAN
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
OHSU Knight Cancer Institute
|
3P30CA069533-19S1
|
$124,990
|
DRUKER, BRIAN
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
OHSU Knight Cancer Institute
|
3P30CA069533-19S2
|
$174,792
|
DRUKER, BRIAN
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Effects of Cytosine Modifications on Transcription Factor Binding
|
ZIC BC 011724
|
$136,721
|
Durell, Stewart
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
3P30CA047904-29S1
|
$115,192
|
FERRIS, ROBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Cancer Center Support Grant
|
3P30CA047904-29S2
|
$55,932
|
FERRIS, ROBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Cancer Center Support Grant
|
3P30CA047904-29S3
|
$175,000
|
FERRIS, ROBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Cancer Center Support Grant
|
5P30CA047904-29
|
$5,129,654
|
FERRIS, ROBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Clinical Pharmacogenetics
|
ZIA BC 010627
|
$738,087
|
Figg, William
|
CCR (NCI)
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-52S1
|
$137,250
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-52S2
|
$250,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-52S3
|
$125,000
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Comprehensive Cancer Center Program at Fox Chase
|
5P30CA006927-52
|
$2,763,834
|
FISHER, RICHARD
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Exploring the Therapeutic Potential of Stem Cell Biology in Gliomas
|
ZIA BC 011640
|
$194,156
|
Gilbert, Mark
|
CCR (NCI)
|
|
Rare Central Nervous System Cancers Initiative
|
ZIA BC 011643
|
$271,818
|
Gilbert, Mark
|
CCR (NCI)
|
|
Identifying New Glioma-Associated Tumor Suppressors & Oncogenes
|
ZIA BC 011647
|
$271,818
|
Gilbert, Mark
|
CCR (NCI)
|
|
Brain Tumor Immunotherapy
|
ZIA BC 011714
|
$271,818
|
Gilbert, Mark
|
CCR (NCI)
|
|
Bioinformatics: Characterizing Brain Tumor Date
|
ZIA BC 011784
|
$77,662
|
Gilbert, Mark
|
CCR (NCI)
|
|
Pre-clinical Translational Research Facility
|
ZIC BC 011641
|
$1,242,597
|
Gilbert, Mark
|
CCR (NCI)
|
|
Brain Tumor Clinical and Clinical Research Program
|
ZID BC 011642
|
$1,553,246
|
Gilbert, Mark
|
CCR (NCI)
|
|
Pediatric Oncology Branch Behavioral Science Core
|
ZID BC 011517
|
$895,830
|
Glod, John
|
CCR (NCI)
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,583,320
|
Glod, John
|
CCR (NCI)
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
ZIA BC 005598
|
$587,732
|
Gottesman, Michael
|
CCR (NCI)
|
|
Mechanism, Regulation and Application of miRNA pathway in cancer
|
ZIA BC 011566
|
$686,859
|
Gu, Shuo
|
CCR (NCI)
|
|
Development of new antibody-based cancer therapies
|
ZIA BC 010891
|
$942,291
|
Ho, Mitchell
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|